Tenax Therapeutics, Inc. (TENX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-14. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 61/100 (HIGH), 61.1 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 67.67% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?
- Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
- Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
- Tenax Therapeutics’ stock crashes on Phase III trial failure
- Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103
- Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Tenax Therapeutics, Inc..
Full TENX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.